Given the pivotal role of CXCL9/10 in facilitating T cell-mediated antitumor immune responses, this study evaluates the efficacy of in situ vaccination with CXCL9/10-engineered DC (CXCL9/10-DC) to enhance the efficacy of ICB immunotherapies in murine NSCLC models. The gene discussed is CXCL9; the disease is non-small cell lung carcinoma.